ipilimumab
ESMO 2018: NSCLC - Checkpoint inhibitors for early-stage disease
Growing evidence raises hopes for neoadjuvant checkpoint inhibition in early NSCLC. At ESMO 2018, exciting new preliminary phase II data from the NEOSTAR trial have emerged supporting this concept.
